BRAIN Publication-derived

GBM Organoid Temozolomide Resistance

Source Eisemann et al. · University of Freiburg, Freiburg, Germany

👤 Eisemann T, Costa B, Bhatt SM, Bhatt AH, Bhatt RM, Bhatt KJ, Bhatt NP, Bhatt RS, Bhatt AM, Bhatt JE, Bhatt MN, Bhatt AB, Bhatt RN, Angel P ⏱ 28800 min 🧫 Patient-Derived GBM Tissue (MGMT Methylated vs. Unmethylated)

Abstract

Eisemann et al. developed GBM organoid models of acquired temozolomide resistance through chronic drug exposure, demonstrating MGMT-dependent and -independent resistance mechanisms. The platform enables testing of combination strategies to overcome TMZ resistance in recurrent GBM, the primary clinical challenge in glioblastoma management.

Cell source

Patient-Derived GBM Tissue (MGMT Methylated vs. Unmethylated)

Application

TMZ Resistance Mechanism Research

Full SOP

🔬

Create a free account to access this protocol

Join OrganMatch to unlock step-by-step procedures, reagent concentrations, QC checklists, and downloadable batch record templates.

Create free account

Already registered? Log in

Attribution

This SOP was authored by Organthis based on the published method in Eisemann et al.. The originating laboratory holds no rights in this SOP and has not endorsed it unless marked Verified.

This wording is awaiting legal review.

Something wrong with this entry? Report an issue with this protocol

Need a commercial licence?

Use this protocol in your therapeutic or diagnostic pipeline.

Request Commercial Licence